|Bid||104.38 x 800|
|Ask||105.10 x 800|
|Day's Range||103.12 - 104.93|
|52 Week Range||85.58 - 131.73|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||45.08|
|Earnings Date||Apr 18, 2022 - Apr 22, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.65|
The currency headwinds slamming medtech caught up to Edwards Lifesciences late Thursday, leading EW stock to topple on a guidance haircut.
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
With me on today's call are Mike Mussallem, chairman and chief executive officer; and Scott Ullem, chief financial officer. Also joining us for the Q&A portion of the call today will be Larry Wood, our global leader of TAVR; Bernard Zovighian, our global leader of TMTT; and Daveen Chopra, our global leader of Surgical Structural Heart.